-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
San Francisco, USA and Suzhou, China September 30, 2021/PRNewswire/ - Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, and its own A biopharmaceutical company that is an innovative drug for major diseases such as immunity, today announced that its KRAS G12C inhibitor IBI351 phase I/II clinical study (ClinicalTrials.
This study is an open-label, multi-center phase I/II clinical study in patients with advanced solid tumors (non-small cell lung cancer and gastrointestinal tumors) carrying KRAS G12C mutations in China.
Professor Wu Yilong, the principal investigator of the study, the life director of Guangdong Provincial People’s Hospital and the honorary director of Guangdong Lung Cancer Research Institute, pointed out: “KRAS is the most common RAS protein subtype.
Dr.
Dr.
About IBI351 (KRAS G12C inhibitor)
IBI351 (Jinfang Pharmaceutical Research and Development Code GFH925) is a highly efficient oral new molecular entity compound independently developed by Jinfang Pharmaceutical with complete intellectual property rights.
In September 2021, Jinfang Pharmaceutical and Cinda Biotech reached a strategic cooperation.
About Cinda Bio
"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio
Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model
Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center, and Hanmi of South Korea.
Forward-looking statement
The information published in this press release may contain certain forward-looking statements
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made
Source: Cinda Bio
